Status:
COMPLETED
The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans
Lead Sponsor:
Albert Einstein College of Medicine
Collaborating Sponsors:
Takeda
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to investigate the acute effects of the thiazolidinedione agent pioglitazone (which has combined PPAR alpha and gamma stimulation) on insulin's ability to suppress glucose...
Detailed Description
Participants in this study were given a supply of either pioglitazone (a medication used to treat diabetes) or matched placebo for a duration of 10 days or 21 days. Changes to the body's response to i...
Eligibility Criteria
Inclusion
- • Individuals with Type 2 Diabetes
Exclusion
- Individuals with bleeding disorders including gastrointestinal reflux disease (GERD), peptic ulcer disease (PUD), any gastrointestinal (GI) bleeding
- High blood pressure
- History of Coronary Artery Disease or chest pain on exertion
Key Trial Info
Start Date :
December 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00179400
Start Date
December 1 2000
End Date
July 1 2011
Last Update
March 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Albert Einstein College of Medicine
The Bronx, New York, United States, 10461